Odronextamab

Multispecific antibody

Approvedregulatory verdict

Evidence outlook

Approved: relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic... (EU)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Systemic Lupus Erythematosus · Phase 1 · investigational in the USDiffuse Large B-Cell Lymphoma · Phase 3 · investigational in the USB-Cell Non-Hodgkin Lymphoma · Phase 3 · investigational in the US

Also approved (2)
EU
  • Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.
  • Monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy
Product first approved 2024EMA

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
B-Cell Non-Hodgkin Lymphoma
NCT06230224 · Regeneron Pharmaceuticals
2024-02-15 – 2028-05-29 · B-Cell Non-Hodgkin Lymphoma (B-NHL)
What this study did
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Phase 2/3 (1)
B-Cell Non-Hodgkin Lymphoma
NCT05991388 · University of Birmingham
2024-05-02 – 2033-05-01 · B-cell Non Hodgkin Lymphoma
What this study did
Phase 2 (4)
B-Cell Non-Hodgkin Lymphoma
NCT03888105 · Regeneron Pharmaceuticals
2019-11-13 – 2028-12-15 · B-cell Non-Hodgkin Lymphoma (B-NHL)
What this study did
Diffuse Large B-Cell Lymphoma
NCT06784726 · University of Washington
2025-09-04 – 2033-04-11 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT06854159 · University of California, Davis
2025-08-07 – 2029-01 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
Follicular Lymphoma
NCT07128641 · Gottfried von Keudell, MD PhD
2025-09-08 – 2028-01-02 · Follicular Lymphoma, Lymphoma
What this study did
Phase 1/2 (1)
Diffuse Large B-Cell Lymphoma
NCT07887750 · Regeneron Pharmaceuticals
2026-12-07 – 2029-11-01 · Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
Phase 1 (5)
B-Cell Non-Hodgkin Lymphoma
NCT05685173 · Regeneron Pharmaceuticals
2023-04-20 – 2030-01-13 · B-cell Non-Hodgkins Lymphoma (B-NHL)
What this study did
Diffuse Large B-Cell Lymphoma
NCT06735664 · City of Hope Medical Center
2025-08-14 – 2027-12-13 · Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
What this study did
Systemic Lupus Erythematosus
Other / comorbidity
NCT02651662 · Regeneron Pharmaceuticals
2016-01-11 – 2026-04-29 · Relapsed/Refractory Aggressive B-Cell Lymphoma
What this study did
NCT02290951 · Regeneron Pharmaceuticals
2015-01-09 – 2025-08-21 · Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for B-Cell Non-Hodgkin Lymphoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Odronextamab: this drugPhase 3Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4512Phase 1/2Antibody–drug conjugateCD22not yet gradedNo reviewed efficacy summary in this indication
CND261
Phase 1(overall)
Biologic (subtype unspecified)CD20 x CD3
not yet graded(overall)
No reviewed efficacy summary in this indication
JNJ-88998377Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Plamotamab
Phase 1(overall)
Multispecific antibodyCD20 x CD3
not yet graded(overall)
No reviewed efficacy summary in this indication
REGN5837Phase 1Multispecific antibodyCD22 x CD28not yet gradedNo reviewed efficacy summary in this indication
SHR-3079Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Vispacabtagene RegedleucelDiscontinuedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Odronextamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (1)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-01-02 · NCT07128641 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-12-13 · NCT06735664 · CT.gov ↗
What to watch
2028 (5)
February 2028 (1)
Phase 3Follicular LymphomaRecruiting
Est. primary completion 2028-02-29 · NCT06091254 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-03-30 · NCT06091865 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-04-10 · NCT06784726 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3B-Cell Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2028-05-29 · NCT06230224 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-10 · NCT06854159 · CT.gov ↗
What to watch
2029 (4)
February 2029 (1)
Phase 1B-Cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2029-02-16 · NCT05685173 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2029-07-29 · NCT06097364 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1Systemic Lupus ErythematosusRecruiting
Est. primary completion 2029-09-10 · NCT06975787 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1/2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2029-11-01 · NCT07887750 · CT.gov ↗
What to watch
2031 (2)
April 2031 (1)
Phase 3Follicular LymphomaRecruiting
Est. primary completion 2031-04-30 · NCT06149286 · CT.gov ↗
What to watch
May 2031 (1)
Phase 2/3B-Cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2031-05-01 · NCT05991388 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

February 2027FDA action dateFDA decision on the odronextamab BLA in relapsed/refractory DLBCL expected February 2027
US, FDA · Source ↗

Recent

30 July 2025Complete response letterFDA issues complete response letter for the odronextamab BLA in relapsed/refractory follicular lymphoma
US, FDA · FDA · Source ↗